Cell Care Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Cell Care Therapeutics's estimated annual revenue is currently $155k per year.
- Cell Care Therapeutics's estimated revenue per employee is $155,000
Employee Data
- Cell Care Therapeutics has 1 Employees.
- Cell Care Therapeutics grew their employee count by -90% last year.
Cell Care Therapeutics's People
Name | Title | Email/Phone |
---|---|---|
1 | Co-Founder, CEO, President | Reveal Email/Phone |
2 | Chief Medical Officer ; Pediatric Ophthalmologist | Reveal Email/Phone |
3 | Chief Medical Officer | Reveal Email/Phone |
4 | CMO Cell Care Therapeutics | Reveal Email/Phone |
Cell Care Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5.4M | 70 | -8% | $53M | N/A |
#2 | $32.4M | 167 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.8M | 18 | 13% | N/A | N/A |
#5 | $0.8M | 5 | -50% | N/A | N/A |
#6 | $0.8M | 10 | 0% | N/A | N/A |
#7 | $14M | 90 | -12% | N/A | N/A |
#8 | $0.4M | 336 | 10% | $236.7M | N/A |
#9 | $4.8M | 62 | -74% | $160M | N/A |
#10 | $3.7M | 24 | -8% | N/A | N/A |
What Is Cell Care Therapeutics?
Cell Care Therapeutics is developing a new class of biologics that are derived from the secreted proteins and exosomes of mesenchymal stromal cells (MSCs). The company’s novel secretome platform harnesses the signaling molecules of MSCs to promote the health of blood vessels and their surrounding tissue. The company is developing its first product for the treatment of diabetic macular edema, the leading cause of vision loss in working age adults.
keywords:N/AN/A
Total Funding
1
Number of Employees
$155k
Revenue (est)
-90%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $0.1M | 2 | 0% | N/A |
#2 | $0.3M | 3 | 0% | N/A |
#3 | $0.6M | 4 | -33% | N/A |
#4 | $0.4M | 5 | 0% | N/A |
#5 | $0.4M | 5 | -17% | N/A |